The World Health Organization warns that one in six bacterial infections is now resistant to standard treatments . The phenomenon of antimicrobial resistance (AMR) continues to grow by 5 to 15% annually in many countries, jeopardizing key achievements of modern medicine.

The concern is especially great in urinary tract and bloodstream infections: there, resistance affects 15–20% of cases. In regions with less access to healthcare, this risk is even greater, as the indiscriminate use of antibiotics and the lack of accurate diagnosis exacerbate the problem.

The situation demands urgent action: investing in R&D for new antimicrobials, strengthening surveillance and rapid diagnostic programs, regulating the use of drugs in human and veterinary medicine, and improving equitable access to effective treatments.

For women, this problem has an additional impact: urinary tract infections, gynecological complications, or repeated antibiotic use can become more difficult to treat. Prevention, proper hygiene, and medical follow-up become essential.

This data is a wake-up call: medicine cannot afford to regress. If we invest today in innovation, responsibility, and equity, we can contain this resistance before it completely overwhelms us.